Principle of Binding Equations for Drug-binding Studies

Binding equation and binding parameters
For experiments carried out at large molar protein/dye ratios, it was assumed that only strong sites were active in binding dye. For simplicity, these strong binding sites were also assumed to be identical and to act independently. If these assumptions are valid, the site-binding model could be constructed, and the binding equation described by Scatchard is given by 10 ν = .
Here, ν is the average number of dye molecules bound per protein molecule, n is the number of (strong) binding sites, K is the intrinsic binding constant, and [D] is the concentration of free (unbound) dye. For other equivalent or modified linear forms of Eq. (1) could be found from the literature. 2, 7, 8, 11 As for the Scatchard equation, because the assay of [D] is a problem in many cases, practical formulas for small-molecule ligands to bio-macromolecules have been derived by us based on Scatchard's site-binding model and florescence quenching. The following is an introduction.
In the case of fluorescence caused only by a protein at a selected wavelength, the relationship between the concentration of protein and the fluorescence intensity can be described by
F0/F = [Pt]/[P].
According to the definition of n, another equation is also known,
where [Pt] is the total protein concentration and [Dt] is the final dye concentration. F0 and F are, respectively, the fluorescence intensity in the absence of a quencher and in its presence at [D] concentration, ∆F = F0 -F.
The following equations are obtained by combining Eqs.
(1)
and (2):
Equation (2) can be rewritten as = .
When Eq. (3) is introduced into the above equation,
If the concentration of protein is fixed and a range of doses for the dye is prepared, the binding constant (K) and the binding site (n) can be estimated at the same time without [D] , the concentration of free dye. The Levenberg-Marquardt algorithm is adopted for data-fitting by Eq. (4).
Moreover, based on the site-binding model, if a smallmolecule ligand interacts with a bio-macromolecule and forms a static complex, the following equilibrium can be reached:
Here, DnP is the complex. The constant of equilibrium is written according to the theory of equilibrium,
Presuming that the concentration of small-molecule ligands that are bound to the bio-macromolecules is [Db], the following relationship could be made from the stoichiometric coefficient of Eq. (5):
[Pt]
Equations (1) and (2) yielded = ,
Introducing Eq. (8) into Eq. (6),
This leads to the following results by making use of the
= 0.5(1 + + -0.5 .
When introducing Eq. (12) into Eq. (11), Eq. (13) is defined as
Thus, introducing Eqs. (8) and (9) into Eq. (13), another datafitting equation for the small-molecule ligand interacting with the bio-macromolecule is obtained when Eq. (6) is commonly used,
This indicates that the binding constant (K) and binding site (n) can be obtained at the same time by using a least-squares algorithm for data-fitting according to Eq. (14) .
While starting from Eq. (10), the following results could be generalized:
Equation (15) can be expressed as a function by using Eq. (2), as follows:
Thus, the binding constant (K) and binding site (n) can also be deduced from formula (16) by the same algorithm as Eq. (14). Equations (4), (14) and (16) , although different forms are expressed, can fit the binding data and, in principle, the results of fitting the binding data, the binding parameters, K and n, must be equal. By introducing Eqs. (2) and (12) into Eq. (14) , and performing mathematical transformations, Eq. (4) can be generalized. Equation (4) can also be reached by introducing the formula ∆F/F = F0/F -1 and Eq. (12) into Eq. (16) , and making some mathematical derivations.
For different experiment data, these fitting equations can conveniently be used to obtain the binding parameters.
Energy transfer between dye and BSA
According to Förster non-radioactive energy transfer theory, 12,13 the energy-transfer effect is related not only to the distance between the acceptor and donor, but also to the critical energy-transfer distance (R0), i.e.,
Here, R0 is the critical distance when the transfer efficiency is 50%,
where K 2 is the spatial orientation factor of the dipole, N is the refractive index of the medium, Φ is the fluorescence quantum yield of the donor, J is the overlap integral of the fluorescence emission spectrum of the donor and the absorption spectrum of the acceptor. Therefore, (19) where F(λ) is the fluorescence intensity of the fluorescent donor at wavelength λ and ε(λ) is the molar absorptivity of the
acceptor at wavelength λ. Thus, the energy-transfer efficiency is
Experimental
Apparatus and reagents All of the fluorescence measurements were carried out on a M850 recording spectrofluorimeter (Hitachi). A UV-240 recording spectrophotometer (Shimadzu) was used for scanning the UV spectrum. All pH measurements were made with a pHS-2 digital pH-meter (Shanghai Lei Ci Device works, Shanghai China) with a combinational glass calomel electrode. BSA and gatifloxacin (Huamei Biotechnological, Shanghai) were used. The solutions of metal ions (1.00 × 10 -3 mol l -1 ) and 0.05 mol l -1 Tris-HCl buffer of pH = 7.0 (0.1 mol l -1 NaCl was used to keep the ionic strength constant) were prepared. All reagents were of analytical grade and double-distilled water was used throughout.
Procedures
BSA and gatifloxacin were dissolved in Tris-HCl buffer, the concentrations of BSA and gatifloxacin were 1.00 × 10 -5 mol l -1 and 1.00 × 10 -3 mol l -1 , respectively. The gatifloxacin-metal ions solution (the ratio = 1:1) was prepared by mixing a solution of metal ions and gatifloxacin in the buffer; the mixing samples contained 1.00 × 10 -3 mol l -1 solutes. To a 1.0 cm quartz cell, the BSA solution was added to 2.5 ml, and the range of the drug solution was gradually titrateded into the cell using a microinjector. The accumulated volumes were 10, 20, 30, 40, 50, 62, 72, and 83 µl (the total accumulated volume < 200 µl). In studies of the effect for metal ions, the drug-metal ions concentration varied according to the same scheme. Fluorescence quenching spectra were obtained at excitation and emission wavelengths of 282 nm and 300 -500 nm, respectively. The range of synchronous scanning was λex = 250 -275 nm, λem = 310 -290 nm, where the differences in the wavelengths (∆λ) were 60 nm (λex = 250 nm, λem = 310 nm) and 15 nm (λex = 275 nm, λem = 290 nm). For absorption spectra (UV) experiments, samples of gatifloxacin, gatifloxacin-Fe 3+ (1:1), gatifloxacin-Cu 2+ (1:1) was brought to 1.0 cm cuvette versus a blank of buffer. The absorbances were read and a spectral scanning curve was made.
Results and Discussion
The quenching mechanism and quenching constants
The fluorescence quenching mechanism usually involves static quenching and dynamic quenching.
The dynamic quenching mechanism can be described by the Stern-Volmer equation. The present work was aimed at investigating whether gatifloxacin interacts with BSA (a molecular protein containing two tryptophan residues, Trp-212 and Trp-134) and upon which the quenching mechanism acts. Increasing the gatifloxacin concentrations caused a reduction in the fluorescence of the tryptophen residues. It is interpreted that the compound was formed between gatifloxacin and BSA. In order to confirm the quenching mechanism, the procedure that the fluorescence quenching data was disposed by us was assumed to be dynamic quenching. The Stern-Volmer equation is 15, 16 Obviously, the rate constant of the protein quenching procedure initiated by gatifloxacin is greater than the Kq of the scatter procedure. This shows that the quenching is not initiated by dynamic quenching, but by compound formation.
Fluorescence spectra, binding constant and binding sites Figure 1 shows the fluorescence spectra of gatifloxacin and BSA. The fluorescence emission lines of the gatifluoxacin-BSA (1:1) mixturing system and the gatifloxacin solution in the presence of Fe 3+ and Cu 2+ can also be observed in Fig. 1 . It is well known that BSA has strong fluorescence at λex/λem = 282/343 nm. For the case that the solution condition agrees with our studies, Fig. 1 nm for gatifloxacin-Cu 2+ (1:1) fluorescence. In addition, the BSA fluorescence spectra is somewhat quenched. This means that th interaction has occurred and the energy has been transferred.
The fluorescence quenching spectra of BSA in Tris-HCl buffer with increasing gatifloxacin concentration and a fixed BSA concentration (1.00 × 10 -5 mol l -1 ) are shown in Fig. 2 . It is obvious that the concentration of gatifloxacin gradually increases with the titration and the fluorescence intensity of BSA decreases. At the same time, the fluorescence emission peak of gatifloxacin is gradually enhanced. A well-defined isobestic point is observed at 405 nm, which is direct evidence of drug-protein complex formation.
After measurements of the fluorescence quenching on BSA at 343 nm were conducted, the Levenberg-Marquardt (L-M) and least squares (L-s) algorithm for data-fitting was assessed by Eqs. (4), (14) and (16) . Figure 3 shows the fitting curve and Table 1 gives the fitting results.
A good relationship between the experiment points and the calculated values shows that the interaction with gatifloxacin bound to BSA agrees with the model of site-binding. It is also indicated that there is a stronger binding force between gatifloxacin and BSA, and that a binding site would be formed.
Similar results were found for fitting binding data using Eqs. (4), (14) , and (16) . According to theoretical analysis, the calculated values for the binding parameters by three fitting equations must be equal; however, in practice these circumstances are almost never met.
Binding distance between the drug and the amino acid residues of BSA
The overlap of the absorption spectrum of gatifloxacin and the fluorescence emission spectrum of BSA is shown in Fig. 4 . The overlap integral (J) was evaluated by integrating the spectra in Fig. 4 for λ = 250 -500 nm. It was calculated to be 1.50 × 10 -14 cm 3 dm 3 mol -1 . Under these experimental conditions, the distance corresponding to 50% energy transfer from BSA to gatifloxacin can be estimated to be R0 = 2.58 nm from Eq. (18) using K 2 = 2/3, N = 1.336, Φ = 0.118. [17] [18] [19] [20] Moreover, the energytransfer effect is E = 0.3652 from Eq. (20) and the binding distance between gatifloxacin and the amino acid residue in BSA is r = 2.82 nm.
Effect of metal ions on the formation constant between the drug and the protein
There was a slight color change and a shorter dissolved time in the solution of gatifloxacin in Tris-HCl with the addition of Fe 3+ and Cu 2+ ions to the system. This suggested that a gatifloxacin-ion stable complex might have been formed. Slight 
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change in the wavelength and absorbance for the absorption peak were observed in the UV absorption spectrum for the gatifloxacin-ion system. This shows that there was an interaction between the metal ions and gatifloxacin. However, researches have previously indicated there is a binding reaction between metal ions and protein, and the presence of metal ions directly affects the binding between the drug and the protein. 21, 22 Further, in order to study the effect of metal ions on the binding between drug and BSA, the fluorescence quenching spectra, the fluorescence of BSA and the absorption spectrum of gatifloxacin-metal ions were obtained under the same apparatus conditions as mentioned above and shown in Figs. 5 and 6. Some binding parameters were determined in the presence of Fe 3+ and Cu 2+ , and a data-fitting was made by Eq. (4) at 25˚C. The results are given in Table 2 .
There are different isobestic points from the gatifloxacinprotein complex formed at 409 nm and 413 nm. It could be demonstrated that a different complex from the gatifloxacinprotein was formed. Table 2 shows that the combination metal ions with the drug increased the binding constants of the drugprotein, and reduced the binding distance. The energy-transfer efficiency of the non-radioactive process has an ascending trend. These phenomena imply that the binding force between the protein and the drug had been enhanced in the presence of ions, thus lengthening both the storage time of the drug in blood plasma and the effectiveness.
The upper right of Figs. 5 and 6 show the fluorescence quenching spectra between the protein and the ions of Fe 3+ and Cu 2+ . This experiment illustrates that Fe 3+ and Cu 2+ are not effective quenchers for BSA, although it can be bound to protein. With the titration of ions and the concentration of ions being in sufficient excess such that for each protein molecule, the quenching effect is gradually noticeable. Therefore, it is possible that the fluorescence quenching of dynamic collisions by the metal ions can occur.
From the UV absorption spectrum, we deduced the gatifloxacin-ion two-component complex formed. The different complexes could be demonstrated based on the different isobestic points of the protein-gatifloxacin-ion system from the gatifloxacin-protein system. On the other hand, the influence of the ions on the protein fluorescence spectrum was not notable. It could be suggested that the ternary complex formed between BSA and gatifloxacin-protein complex. However, the evidence for a ternary complex in this study is not sufficient, and the crystal structure has not been obtained up to now. Thus, the protein-gatifloxacin-ion ternary complex should be further verified. However, the effect of metal ions on the binding between gatifloxacin and BSA can be verified through this type of experiment.
Effect of the drug on the BSA conformation
The conformational changes of BSA were evaluated by measuring the synchronous fluorescence intensity of protein amino acid residues, both before and after the addition of gatifloxacin.
In this work, synchronous fluorescence spectroscopy was used to study the synchronous fluorescence characteristics of BSA at different scanning intervals (∆λ = λemission -λexcitation). When ∆λ = 15 nm, the spectrum characteristic of the protein tyrosine residues was observed, and when ∆λ = 60 nm, the spectrum characteristic of protein tryptophan residues was observed. The authors suggested a useful method to study the environment of amino acid residues is to measure the possible shift in the wavelength emission maximum (λmax). 23, 24 The shift in the position of the emission maximum corresponds to the changes in the polarity around the chromophore molecule. Thus, the conformation changes of BSA can be evaluated by a measurement.
With the concentration of the protein being unchanged and the concentration of gatifloxacin increasing by titration, the synchronous spectroscopy was scanned at ∆λ = 15 nm and ∆λ = 60 nm (shown in Figs. 7(A) and 7(B), respectively) . The effect of gatifloxacin on the tyrosine and tryptophan residue fluorescence intensity of BSA indicates that the main contribution to the fluorescence intensity of BSA was tryptophan residues. Figure 7 also shows the effect of gatifloxacin on the emission maximum with the process of titration.
A slightly stronger blue-shift of tryptophan fluorescence upon the addition of the drug was observed, and the emission maximum of tyrosine kept its position. This shift indicates that tryptophan residues were placed in a more hydrophobic environment, and less exposed to the solvent. This may be due to the gatifloxacin insert in BSA molecules, and consequently rearrange the tryptophan microenvironment. It also suggested that the environments of tryptophan residues in pure albumin solution are relatively polar. Binding of the gatifloxacin changes the environments to apolar ones. The shift in polarity is brought about by conformational changes due to the interaction between albumin and the ligand molecule.
